Syncona’s Chief Investment Officer, Chris Hollowood and Syncona Partner, Dominic Schmidt explain how Syncona has built a globally leading platform of unpartnered gene therapy assets.
Syncona has one of the largest and highest quality gene therapy platforms globally with the potential to deliver dramatic efficacy across the tens of thousands of known genetic diseases.
“Our companies are talking to and learning from each other. As they are domain focused and not competing, it really enables those interactions between them”
Dominic SchmidtPartner, Syncona
We have built companies targeting genetic diseases in the key tissue compartments where gene therapy has shown dramatic patient impact that gene therapy can be effective. These include: the retina, the liver and the central nervous system. Our ambition is ultimately to address the most prevalent diseases in each tissue compartment.